Radiolabelled PSMA PET/CT in breast cancer. A systematic review

Nucl Med Rev Cent East Eur. 2020;23(1):32-35. doi: 10.5603/NMR.2020.0004.

Abstract

Background: Radiolabelled prostate-specific membrane antigen (PSMA)-based PET/CT is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumours. The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT in breast cancer.

Material and methods: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane Library databases was conducted to find relevant published articles about the diagnostic performance of radiolabelled PSMA PET/CT in breast cancer.

Results: The comprehensive computer literature search revealed 652 articles. On reviewing the titles and abstracts, 640 articles were excluded because the reported data were not within the field of interest of this review. Twelve articles were selected and retrieved in full-text version; no additional study was found when screening the references of these articles. In total, 12 articles were included in the systematic review.

Conclusions: Further studies enrolling a wider population are needed to clarify the.

Keywords: PET; PSMA; breast cancer; positron emission tomography; prostate specific membrane antibodies.

Publication types

  • Systematic Review

MeSH terms

  • Antigens, Surface / metabolism*
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / metabolism*
  • Glutamate Carboxypeptidase II / metabolism*
  • Humans
  • Isotope Labeling
  • Positron Emission Tomography Computed Tomography / methods*

Substances

  • Antigens, Surface
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II